He has a Virginian accent, a "good ol' boy" speaking style, and a penchant for mischief. įoghorn debuted 31 August 1946 in the Henery Hawk short Walky Talky Hawky.įoghorn is a large, anthropomorphic adult rooster with a red head, long red tailfeathers, and yellow talons with short yellow claws.
Both parts of the name suggest the association with "Senator Claghorn." According to Leonard Maltin, the character's voice was also patterned after a hard-of-hearing West Coast-only radio character from the 1930s, known simply as The Sheriff, in a radio program called Blue Monday Jamboree. At its most raucous, it sounds similar to that of another Blanc voice: Yosemite Sam (an almost exclusive Friz Freleng character). Ī “Leghorn” is a breed of chicken (since it was an Italian breed that makes him Italian-American), and “Foghorn” describes the character's loud, overbearing voice. The rooster adopted many of Claghorn's catchphrases, such as "That's a joke, I say, that's a joke, son." Delmar had based the character of Claghorn upon a Texas rancher who was fond of saying this.
Fog horn leg horn video trial#
In April, The company paused enrollment on its Phase 1 trial of FHD-609 in patients with synovial sarcoma and SMARCB1-deleted tumors after a patient had a severe heart-related safety event.Foghorn Leghorn was directly inspired by the popular character Senator Claghorn, a blustery Southern politician played by Kenny Delmar who was a regular character in The Fred Allen Show, a popular radio show of the 1940s.
Fog horn leg horn video full#
In May 2022, the FDA instituted a partial clinical hold on Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory AML and myelodysplastic syndrome, converted to a full clinical hold in August.
Preliminary data on immune modulation markers in the tumor microenvironment also indicated the potential for combination treatment with checkpoint inhibitors.įoghorn intends to initiate a Phase 1 study of FHD-286 in combination with decitabine or cytarabine for relapsed and/or refractory AML patients, with the first patient scheduled to receive the treatment.Įarlier this month, the FDA lifted the clinical hold on the Phase 1 monotherapy dose escalation study of FHD-286 in acute myelogenous leukemia (AML) and myelodysplastic syndrome. Circulating tumor DNA reductions supported the observed clinical activity. One patient demonstrated a durable partial response and remained on treatment for over 16 months, while nine patients achieved stable disease.Įight patients exhibited tumor reductions in target lesions. Out of the 73 patients, 47 had target lesions for evaluation. Grade 3 or higher treatment-related events were mainly anemia, asthenia, ALP increase, hypokalemia, muscular weakness, and rash. The most common treatment-related adverse events included dysgeusia, fatigue, AST increase, nausea/vomiting, dry mouth, and rash. The clinical data from the Phase 1 study supported the safety and tolerability of FHD-286. The Phase 1 dose-escalation study of FHD-286 in metastatic uveal melanoma included 73 patients who had received a median of two prior therapies across nine different cohorts. However, Foghorn does not intend to pursue FHD-286 to treat uveal melanoma. These findings further validate the safety and tolerability profile of FHD-286. Foghorn Therapeutics Inc (NASDAQ: FHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in metastatic uveal melanoma (mUM).
0 kommentar(er)
